Levodropropizine, an anti-tussive, is prescribed as a cough-suppressant in adults and children.
As a cough suppressant (Adults):
Consider administration of 60 mg of Levodropropizine, thrice daily. The duration should not exceed more than seven days.
As a cough suppressant (Pediatrics):
For children >2 years, consider administration of 1 mg/kg, thrice daily.
For children >12 years, consider administration of 60 mg of Levodropropizine, thrice daily. The duration should not exceed more than seven days.
The mechanism of action of Levodropropizine exerts peripheral action and suppress cough in patients with non-productive cough.
Levodropropizine is contraindicated in patients with excessive mucus discharge or limited mucociliary functions, severe hepatic disorders and allergy to Levodropropizine.
Levodropropizine can cause dizziness. Do not drive vehicles or operate heavy machineries that need utmost alertness.
Therapeutic Classification; Allergic cough cold
After oral administration of Levodropropizine, the drug is rapidly absorbed in the GIT. The peak plasma concentration can be achieved within 40 minutes after administration of Levodropropizine.
The plasma protein-binding capability of Levodropropizine is about 13%.
Excretion ;83% via urine within 96 hour.
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal